281 related articles for article (PubMed ID: 18257808)
1. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
[TBL] [Abstract][Full Text] [Related]
2. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients.
Akizawa T; Koshikawa S; Iwasaki M;
Ther Apher Dial; 2007 Jun; 11(3):220-6. PubMed ID: 17498005
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan.
Kubota M; Hiramatsu M; Yamakawa M; Fukuhara S; Morita S; Iwasaki M; Akizawa T;
Clin Exp Nephrol; 2011 Dec; 15(6):884-92. PubMed ID: 21898029
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
5. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
6. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
7. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
Hörl WH; Holzer H; Mayer GJ;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
[TBL] [Abstract][Full Text] [Related]
10. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
12. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
[TBL] [Abstract][Full Text] [Related]
13. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
Fang YW; Chang CH
Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
[TBL] [Abstract][Full Text] [Related]
15. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
17. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
19. Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients.
Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M; Uchida K
Adv Perit Dial; 2011; 27():60-4. PubMed ID: 22073831
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]